Wave Life Sciences
Open
$7.13
Prev. Close
$7.14
High
$7.13
Low
$7.11
Market Snapshot
$1.33B
-7.2
-0.69
$108.3M
317
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 317 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Wave Life Sciences reported Q1 2026 sales of $38.25 million, despite incurring a net loss of $26.09 million during the quarter.
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 317 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Recently from Cashu
Wave Life Sciences' WVE-007 Shows Promise in Weight Management and Metabolic Health
Wave Life Sciences Advances Weight Management with WVE-007 Recent findings from a six-month follow-up study reveal promising results for Wave Life Sciences' investigational treatment, WVE-007, in redu…
Pace® Life Sciences Transforms Laboratory Operations with Labguru Integration for Enhanced Efficiency
Revolutionizing Laboratory Operations: Pace® Life Sciences Partners with Labguru Pace® Life Sciences, a prominent player in the contract development and manufacturing organization (CDMO) field, is tra…
Pace® Life Sciences Enhances Efficiency with Labguru Platform for Streamlined Laboratory Operations
Transforming Laboratory Efficiency: Pace® Life Sciences’ Adoption of Labguru Platform In a significant move towards enhancing operational efficiency, Pace® Life Sciences implements Cenevo’s Labguru pl…
Strengthening Data Security in Life Sciences with AI Compliance Initiatives
Elevating Data Security Standards in Life Sciences Through AI Compliance In a rapidly evolving field like life sciences, where innovation drives progress, ensuring compliance with stringent regulatory…